Markets
Alex Karp Palantir CEO
Palantir boss Alex Karp (Andrew Harnik/Getty Images)
so you had a bad day

Palantir falls 11%, worst in the S&P 500

The data analytics and AI software vendor endured its worst day of 2025.

Matt Phillips

Palantir plunged afresh on Thursday amid a broad-based tech stock puke that helped push the Nasdaq Composite Index into a technical correction. (That’s a decline of more than 10% from the tech-heavy index’s recent high, which it hit on December 16, 2024.)

It was the worst day of 2025 for Palantir, whose shares were the best performer in the S&P 500 last year, rising 340%. That romp made it a favorite of retail stock traders.

But that rise — which was supercharged by the election of President Trump — also pushed the company’s valuation to levels that many orthodox investors saw as unsustainable.

In recent weeks that have seen a deep uncertainty related to the Trump administration’s trade and foreign policy, as well as signs of an incipient economic slowdown, the market has started to stumble.

Palantir’s tumble has been far worse after reports that the White House was planning large cuts to defense spending. (Palantir’s largest customer is the US government.)

Continued selling by company insiders, including CEO Alex Karp, has also become a point of debate among some investors.

The stock is down more than 35% since its February 18 high. But OG investors are still sitting on huge gains: Palantir shares are more than 870% higher than they were two years ago.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets
Luke Kawa

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.